MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody

Targeting cancer antigens by T cell-engaging bispecific antibody (BiAb) or chimeric antigen receptor T cell therapy has achieved successes in hematological cancers, but attempts to use it to fight solid cancers have been disappointing, in part due to antigen escape. MEK inhibitor had limited activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongjian, Huang, Cheng, Zhang, Zongliang, Feng, Yunyu, Wang, Zeng, Tang, Xin, Zhong, Kunhong, Hu, Yating, Guo, Gang, Zhou, Liangxue, Guo, Wenhao, Xu, Jianguo, Yang, Hui, Tong, Aiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477310/
https://www.ncbi.nlm.nih.gov/pubmed/32984002
http://dx.doi.org/10.3389/fonc.2020.01527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477310/
https://www.ncbi.nlm.nih.gov/pubmed/32984002
http://dx.doi.org/10.3389/fonc.2020.01527

Ejemplares similares